"DALP", DNP-aminohexanoic acid-Lys-aminopropanol

5 mg 315 € available

Art. No. D008
Synonym (S)-6-Amino-2-(6-(2,4-dinitrophenylamino)hexanamido)-N-(3-hydroxypropyl)hexanamide trifluoroacetate; 3-[Nα[Nε-[2', 4'-dinitrophenyl]-amino-n-hexanoyl]-L-lysylamido]-propane-1-ol
Molecular Formula C23H35F3N6O9 (free base: C21H34N6O7)
Molecular Weight 596.55 (free base: 482.53)
Purity by HPLC >95 % (214 nm)
Appearance Yellow resin-like solid
Solubility 25 μM in 0.4% (v/v) DMSO / aqueous buffers
Pre-dissolve e.g. 3.72 mg in 1 ml DMSO (6.25 mM stock) - dilute 1:250 with buffer to obtain a 25 μM solution.
DMSO-stock-solution can be stored at -20°C for at least 4 weeks.
Application Amine donor substrate for transglutaminases. In the parent molecule DALP-methyl carbamate (D009) the lysine side chain is protected by a carbamoyl moiety rendering the molecule membrane permable. In contrast DALP itself does not show considerable uptake by cells. The Km of DALP is 3 μM and therefore about 50 times lower than that of N-biotinylcadaverine (B002). DALP is non-toxic in cell culture below 1 mM. The dinitrophenyl moiety incorporated into substrate proteins can be detected by a suitable anti-DNP-antibody or by HPLC at 365 nm detection wavelength.
Storage Store at -20°C, desiccate
Reference(s) Nemes, Z. Jr. et al. J Biol Chem. 1997, 272, 20577.
Kiraly, R. et al. FEBS J. 2011, 278, 4717 (Review).


  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.


  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation



  • Canceled and rescheduled: Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

  • 19th International Celiac Disease Symposium

    30.09.2021 - 03.10.2021
    Sorrento, Italy